Tag - SERA

Developments

Analysis shows 22% cut in NICU admissions in first-time pregnancies with Sera’s PreTRM

Sera Prognostics (NASDAQ: SERA) has announced publication of a new subgroup analysis from the PRIME trial demonstrating that its PreTRM Test-guided care in first-time pregnancies significantly improved neonatal...

July 10, 2026

Executive Moves

Dr. Tiffany Inglis joins Sera as CMO

Sera Prognostics (NASDAQ: SERA) has announced the appointment of Tiffany Inglis, MD, FACOG, as chief medical officer (CMO). Dr. Inglis brings extensive clinical leadership expertise to Sera. As CMO, she will lead...

October 1, 2025

Markets

WB starts Sera Prognostics at OP

William Blair launched coverage of Sera Prognostics (NASDAQ:SERA), a pregnancy diagnostics company, with an “outperform” rating. The stock closed at $12.85 on Aug. 6. Analyst Brian Weinstein writes that the current rate...

August 9, 2021

Tag - SERA

Analysis shows 22% cut in NICU admissions in first-time pregnancies with Sera’s PreTRM

Dr. Tiffany Inglis joins Sera as CMO

WB starts Sera Prognostics at OP

Subscribe